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Introduction: Anticoagulation therapies carry a risk of bleeding; reversal agents may be beneﬁcial in cases of severe
bleeding even for anticoagulants with a relatively short half-life, such as the oral factor Xa inhibitor rivaroxaban.
Materials and Methods: We investigated the in vitro reversal effect of prothrombin complex concentrate
(PCC; 0.2-1.0 U/mL), activated PCC (aPCC; 0.2–1.0 U/mL) and recombinant activated factor VII (rFVIIa;
5–50 μg/mL) on rivaroxaban-induced (200–1000 ng/mL) changes in prothrombin time (PT) and thrombin
generation (TG) in plasma, and in thromboelastometry (clotting time [CT]) inwhole blood fromhealthy subjects.
Results: All three agents were partially effective in reversing rivaroxaban-induced anticoagulation but showed
different proﬁles. rFVIIa and aPCC were more effective than PCC in reversing prolongations of PT, CT and TG
lag time; rFVIIa was more effective than aPCC. However, the reversal effect reached a plateau with a maximal
effect of approximately 50%. Inhibition of maximum thrombin concentration was slightly reversed by these
agents; aPCCwas themost effective. In contrast, inhibition of endogenous thrombin potential (ETP)was strongly
reversed by aPCC, with signiﬁcant increases over baseline at low rivaroxaban concentrations. Compared with
aPCC, PCC showed a similar but less effective reversal proﬁle. rFVIIa reversed ETP inhibition by approximately
50%.
Conclusions: The extent of reversal by aPCC, PCC and rFVIIa was dependent on the parameter measured in
rivaroxaban-anticoagulated plasma or blood. ETP measurements may have predictive power for assessing the
reversal potential of PCC or aPCC and may be used to indicate an increased prothrombotic risk.© 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
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. Open access under CC BY-NC-ND licthe limitations of traditional anticoagulants. These limitations include
parenteral administration with unfractionated heparin (UFH), low
molecular weight heparins (LMWHs) and fondaparinux; the risk of
heparin-induced thrombocytopenia with UFH (and, to a lesser extent,
with LMWH); and the narrow therapeutic window, slow onset and
offset of action, variable patient response, need for strict coagulation
monitoring and numerous food and drug interactions with vitamin K
antagonists (VKAs) [1–3]. Rivaroxaban, an oral, direct factor Xa inhibi-
tor, has been assessed in large-scale phase III clinical trials across a
broad spectrum of venous and arterial thromboembolic disorders
[4–11]. In these trials, rivaroxaban was associated with non-inferior
or superior efﬁcacy and with a similar safety proﬁle to the current
standards of care (such as enoxaparin or warfarin). Based on these
results, rivaroxaban is now licensed and used in clinical practice for
the prevention and treatment of several thromboembolic disorders in
adult patients.
All currently available anticoagulants carry a risk of bleeding.
The effects of some traditional anticoagulants can be reversed, for
example, protamine sulphate reverses the effect of UFH and partial-
ly neutralises LMWH, and vitamin K reverses the effect of VKAs.
However, intravenous administration of vitamin K achieves normalense.
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[3]. In patients with VKA-associated major bleeding events, the
American College of Chest Physicians (ACCP) guidelines recom-
mend the administration of four-factor prothrombin complex con-
centrate (PCC) in addition to vitamin K to replace clotting factors
[12]. Currently, no clinically approved reversal agent exists for
any of the direct oral anticoagulants. Of note, reversal agents
would only be considered for the management of severe, life-
threatening bleeding events. Current strategies for managing non-
life threatening bleeding events include discontinuation of
anticoagulation, delay of the next dose or the use of activated char-
coal to reduce drug absorption [13–15]. However, anticoagulants
with short half-lives are less likely to require a reversal agent
than those with long half-lives, because withdrawal of the antico-
agulant will normalise haemostasis. Warfarin reaches its peak anti-
coagulant effect between 72 and 96 hours after the initiation of
therapy and has an effective half-life of between 20 and 60 hours
with a mean of approximately 40 hours [3,16]. Because of the inﬂu-
ence of warfarin on vitamin K-dependent clotting factors, its phar-
macodynamic effects are more prolonged than its pharmacokinetic
effects. In comparison, rivaroxaban has a short half-life (5–9 hours
in younger subjects; 11–13 hours in elderly subjects aged
60–76 years) [17,18]. Furthermore, compared with warfarin,
rivaroxaban was also associated with an improved bleeding proﬁle
in three phase III studies [8–10].
The ability to immediately reverse the anticoagulant effect of
rivaroxabanmay be needed in emergency situations, such as in patients
with a life-threatening bleeding event or in case of urgent surgery.
Recombinant activated factor VII (rFVIIa), activated prothrombin
complex concentrate (aPCC) and PCC are haemostatic agents that
contain a high concentration of coagulation factors and, therefore,
may overcome factor Xa inhibition by enhancing thrombin generation
(TG). rFVIIa and aPCC are approved to stop bleeding in patients with
inhibitor-developing haemophilia [19–23]. PCC is approved and re-
commended for rapid warfarin reversal in patients with serious
bleeding events [12,24,25]. It was anticipated that these agents may
reverse the anticoagulation effect of rivaroxaban. Previous studies in
animals and humans have demonstrated the potential of these agents
in reversing rivaroxaban-induced anticoagulation [26–28].
The aim of this study was to assess the potential of PCC, aPCC and
rFVIIa for the reversal of the anticoagulant activity of rivaroxaban in
human blood in an in vitro system. The effects of these haemostatic
agents on different parameters in terms of the reversal of rivaroxaban-
induced anticoagulation were compared; parameters included
prothrombin time (PT), clotting time (CT) measured by thromboela-
stometry (TEM) and parameters of TG (including lag time, maxi-
mum concentration of thrombin [Cmax], and endogenous thrombin
potential [ETP]).
Materials and Methods
Reagents
Rivaroxaban was prepared by Bayer Pharma AG (Wuppertal,
Germany). Human rFVIIa (NovoSeven®) was supplied by Novo Nordisk
(Copenhagen, Denmark). Nanoﬁltered aPCC (FEIBA NF®) was obtained
from Baxter Germany (Unterschleiβheim, Germany), and four-factor
PCC (Beriplex P/N®) was supplied by CSL Behring (Marburg,
Germany). Rivaroxaban was dissolved in 100% dimethyl sulphoxide
(DMSO) to achieve a stock solution of 1000 μg/mL and was further
diluted in 100% DMSO to obtain plasma concentrations as used in PT
and TEM; a stock solution of 500 μg/mL rivaroxabanwas diluted further
in 25% DMSO to obtain plasma concentrations as used in the TG assay.
Adding rivaroxaban solutions to plasma resulted in DMSO concen-
tration ≤ 1% (1% in the PT and TEM assays; 0.7–0.8% in the TG assay);
these DMSO concentrations did not affect the assays. aPCC and PCCwere reconstituted in demineralised water to obtain stock solutions of
100 U/mL; rFVIIa was reconstituted in demineralised water to obtain a
stock solution of 1000 μg/mL; these stock solutionswere further diluted
in 0.9% saline to be used in assays. When calculating plasma or blood
concentrations, a body weight of 70 kg with a blood volume of 5 L was
assumed. The concentrations of rivaroxaban were chosen to simulate
maximum plasma concentrations in patients treated with 20 mg once
daily (creatinine clearance N 50 mL/min): mean 274 ng/mL (range
175–400 ng/mL) [29] and hypothetical overdoses (up to 1000 ng/mL
in plasma and 1800 ng/mL in whole blood). aPCC concentrations
were chosen to simulate human plasma concentrations of 0.7 U/mL
(as expected after taking the recommended dose of 50 U/kg body
weight); a higher concentration of 1.0 U/mL (recommended dose
range 50–100 U/kg in patients with haemophilia A or B) [30] and the
lower concentrations of 0.2 U/mL and 0.4 U/mL, were also investigated.
The concentrations of PCC were chosen to simulate human plasma con-
centrations of 0.4 U/mL (25 U/kg body weight) and 0.7 U/mL (50 U/kg
body weight) – recommended doses for patients treated with
VKAs (INR 2.0–3.9 or INR N 6.0) [24] – and a lower concentration of
0.2 U/mL and higher concentration of 1.0 U/mL were also investigated.
The lowest concentration of 5 μg/mL rFVIIa was chosen to simulate
human plasma concentrations equivalent to 270 μg/kg (recommended
dose 90 μg/kg every 2 hours) [31], and higher concentrations of
15 μg/mL and 50 μg/mL (corresponding to a concentration 30-times
higher than the Cmax of the approved 90 μg/kg rFVIIa) were also
investigated.
Collection and Preparation of Blood Samples
Individual blood was collected by venipuncture from healthy
subjects who had not received medication in the previous 10 days.
Blood was collected into vacutainer tubes containing 1/10 volume of
3.12% trisodium citrate (Sarstedt, Nümbrecht, Germany). Platelet-poor
plasma (PPP) from individual subjects was obtained by immediate
centrifugation at 1000 g for 20 minutes at room temperature and was
stored in aliquots at−70 °C. PPP of six different subjects was thawed
and pooled directly before measurements were taken (PT and TG
assays). In whole blood, haematocrit was measured to calculate the
individual plasma concentrations of rivaroxaban.
Prothrombin Time
PT was measured in a coagulometer (Amelung KC 10A, Lemgo,
Germany). Samples were prepared as follows: pooled PPP was spiked
with rivaroxaban (200, 500 or 1000 ng/mL) in the presence or absence
of aPCC (0.2, 0.4, 0.7 or 1.0 U/mL; n= 5), PCC (0.2, 0.4, 0.7 or 1.0 U/mL;
n = 7) or rFVIIa (5, 15 or 50 μg/mL; n = 7). Samples (duplicates) were
incubated for 3 minutes at 37 °C and the reaction was started by the
addition of Néoplastine Plus® (Diagnostica Stago, Asnières-sur-Seine,
France) in accordance with the manufacturer’s instructions. Control
curves were generated with the appropriate vehicles (n = 5–12).
Thromboelastometry
CT was determined by TEM using tissue factor (TF) to initiate
coagulation (r ex-tem®; TEM Innovations GmbH, Munich, Germany)
in accordance with the manufacturer’s instructions. Freshly drawn
whole blood samples (duplicates) were prepared as follows: whole
blood was spiked with rivaroxaban (200, 500 or 1000 ng/mL) in the
presence or absence of aPCC (0.2, 0.7 or 1.0 U/mL; n = 5), PCC (0.2,
0.4 or 1.0 U/mL; n = 2–3) or rFVIIa (5, 15 or 50 μg/mL; n = 4).
The blood was stored at room temperature on a rotating mixer and
processed within 15–90 minutes after venipuncture. The reaction was
started by adding r ex-tem (thromboplastin from rabbit brain) and
CaCl2 (star-tem reagent, CaCl2 11.8 mM; ﬁnal concentration) to the
samples in a ROTEM analyser (TEM Innovations GmbH, Munich,
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with the appropriate vehicles (n = 7–15). The plasma concentrations
of rivaroxaban and the haemostatic agents were calculated for each
sample. Plasma concentrations are given as mean values obtained
from the individual donors.
Thrombin Generation Assay
TG was measured using the calibrated automated thrombogram
(CAT; Diagnostica Stago, France) method in accordance with the
manufacturer’s instructions using a ﬂuorometer (Fluoroskan Ascent;
Thermo-Labsystems, Germany). Samples (in triplicate) were prepared
as follows: pooled PPP was spiked with rivaroxaban (200, 500 or
1000 ng/mL) in the presence or absence of aPCC (0.2, 0.4, 0.7 or
1.0 U/mL; n = 5), PCC (0.2, 0.4, 0.7 or 1.0 U/mL; n = 7) or rFVIIa
(5, 15 or 50 μg/mL; n = 6–7). PPP reagent (5 pM; Diagnostica
Stago, France) was added to the samples before the reaction was
started by the addition of FluCa (HEPES pH 7.5 containing CaCl2 and
ﬂuorogenic substrate Z-Gly-Gly-Arg-AMC [Bachem, Switzerland]).
TGwas assessed bymeasuring the cleavage of theﬂuorogenic substrate.
Lag time, Cmax and ETP were determined. Control curves were generated
with the appropriate vehicles (n = 5–8). ETP could not be calculated at
the highest concentrations of aPCC and PCC in rivaroxaban-free plasma,
because the amount of thrombin generated under these conditions
exceeded the upper detection limit of the assay.
Statistical Methods
Analysis of variance (ANOVA) followed by Tukey’smultiple compar-
ison test was used for statistical analysis (Graph Pad Prism version 5.04;
Graph Pad Software Inc., San Diego, CA, USA). Statistical comparisons
were made between rivaroxaban and rivaroxaban plus the haemostatic
agent at each rivaroxaban concentration, as well as between unspiked
control and all spiked samples; p-values b 0.05 were considered to be
statistically signiﬁcant. Results are shown as means ± standard error
of mean (SEM).
Results
Prothrombin Time
Rivaroxaban at 200–1000 ng/mL concentration-dependently
prolonged PT in human plasma by 2.1-fold to 5.5-fold over baseline.
rFVIIa alone at concentrations of between 5 μg/mL and 50 μg/mL
signiﬁcantly shortened PT from 12.9 seconds to a minimum of
7.3 seconds (up to 0.58-fold) (Fig. 1A). All concentrations of rFVIIa
signiﬁcantly reversed rivaroxaban-induced PT prolongation in plas-
ma: by 47–48%, 53–55% and 53–54% with 200, 500 and 1000 ng/mL
rivaroxaban, respectively (Fig. 1A). Because maximal reversal was
already achieved by 5 μg/mL rFVIIa at all concentrations of
rivaroxaban, the concentration dependency of rFVIIa was further in-
vestigated for concentrations between 0.001 μg/mL and 5 μg/mL.
rFVIIa at 0.005 μg/mL was the minimum effective concentration for
the reversal of 1000 ng/mL rivaroxaban in the PT assay (data not
shown). Higher concentrations of rFVIIa reversed rivaroxaban-
induced PT prolongation in a concentration-dependent manner up to
5 μg/mL.
aPCC alone at concentrations between 0.2 U/mL and 1.0 U/mL
shortened PT in a concentration-dependent manner from 12.8 seconds
to 9.2 seconds (up to 0.71-fold) (Fig. 1B). PT prolongation in plasma
containing 200, 500 and 1000 ng/mL rivaroxaban was signiﬁcantly
reversed by 22–38%, 32–49% and 30–47%, respectively, across all con-
centrations of aPCC (Fig. 1B). With aPCC, a ceiling effect of reversal of
rivaroxaban-induced PT prolongation was achieved at 0.7 U/mL
(Fig. 1B). PCC alone at concentrations between 0.2 U/mL and 1.0 U/mL
slightly shortened PT from 13.1 seconds to 12.3 seconds (up to0.94-fold) (Fig. 1C). PCC signiﬁcantly reversed PT prolongation by
15–22% in plasma containing 500 and 1000 ng/mL rivaroxaban. In the
presence of 200 ng/mL rivaroxaban, the reversal effect (11–16%)
did not reach statistical signiﬁcance (Fig. 1C). In summary, the rever-
sal effect decreased in the following order rFVIIa N aPCC N PCC
(Table 1).
Thromboelastometry
In the whole blood coagulation assay, rivaroxaban plasma concentra-
tions between 331 ng/mL and 1807 ng/mL concentration-dependently
prolonged CT from 1.8-fold to 3.7-fold over baseline (Fig. 2).
With rFVIIa alone (9, 27 and 87 μg/mL), CT was reduced up to 0.67-
fold from 98 seconds to 66, 82 and 70 seconds, respectively (Fig. 2A).
Maximum reversal of CT prolongation with 358, 895 and 1807 ng/mL
rivaroxaban by 37–53% was achieved at the lowest concentration of
9 μg/mL rFVIIa. aPCC alone at 0.33, 1.16 and 1.64 U/mL shortened CT
up to 0.7-fold from 93 seconds to 65, 73 and 73 seconds, respectively
(Fig. 2B). CT prolongation with 331, 827 and 1656 ng/mL rivaroxaban
was reversed by 9–25% with 0.33 U/mL and 1.16 U/mL aPCC, and by
24–40% with 1.64 U/mL aPCC, but this effect only reached statistical
signiﬁcance for 1656 ng/mL rivaroxaban. These results indicated that
aPCC partially reversed rivaroxaban-induced prolongation of CT but not
in a concentration-dependent manner and was less effective than rFVIIa
(Table 1). PCC alone (0.35, 0.67 and 1.68 U/mL) did not affect CT and
did not reverse rivaroxaban-induced CT prolongation (Table 1, Fig. 2C).
Thrombin Generation
As expected [32], rivaroxaban affected all parameters of TG in a
concentration-dependent manner. Lag timewas prolonged by between
3.0-fold and 4.9-fold relative to baseline, at rivaroxaban concentrations
of 200, 500 and 1000 ng/mL (Fig. 3). ETPwas inhibited by between 28%
and 84% (Fig. 4), and Cmax was inhibited by between 86% and 97%
relative to baseline at rivaroxaban concentrations of 200, 500 and
1000 ng/mL (Fig. 5).
rFVIIa alone shortened lag time by 0.6-fold relative to baseline
(Fig. 3A), slightly but signiﬁcantly increased Cmax by 9–10% (Fig. 5A)
but had no effect on ETP (Fig. 4A). All concentrations of rFVIIa signiﬁ-
cantly reversed rivaroxaban-induced prolongation of lag time by
50–57% at 200, 500 and 1000 ng/mL rivaroxaban (Fig. 3A). All concen-
trations of rFVIIa signiﬁcantly reversed rivaroxaban-induced ETP
inhibition by 39–56% (Fig. 4A) and Cmax inhibition by 6–18% (although
not all concentrations reached statistical signiﬁcance; Fig. 5A) at 200,
500 and 1000 ng/mL rivaroxaban.
aPCC alone slightly shortened lag time at all concentrations by 20–30%
relative to baseline (Fig. 3B), and increased ETP in a concentration-
dependent manner by 29%, 56% and 99% at 0.2, 0.4 and 0.7 U/mL, respec-
tively (Fig. 4B). In addition, aPCC alone increased Cmax concentration
dependently by 32%, 57%, 83% and 122% over baseline at aPCC concentra-
tions of 0.2, 0.4, 0.7 and 1.0 U/mL, respectively (Fig. 5B). All concentra-
tions of aPCC reversed rivaroxaban-induced prolongation of lag time by
33–47% (Fig. 3B). In plasma spiked with 200 ng/mL rivaroxaban, ETP
was signiﬁcantly increased by 14%, 58% and 81% over baseline at aPCC
concentrations of 0.4, 0.7 and 1.0 U/mL, respectively (Fig. 4B). In plasma
spiked with 500 ng/mL rivaroxaban, reversal of rivaroxaban-induced
ETP inhibitionwas not signiﬁcant with 0.2 U/mL aPCC but was signiﬁcant
with 0.4 U/mL aPCC (89%), whereas ETP increased by 27% and 32% over
baseline with 0.7 U/mL (p b 0.001) and 1.0 U/mL aPCC, respectively
(Fig. 4B). At a concentration of 1000 ng/mL rivaroxaban, ETP inhibition
was reversed by 40–73% at all concentrations of aPCC (p b 0.01 for
concentrations ≥ 0.4 U/mL; Fig. 4B). aPCC (all tested concentrations)
reversed rivaroxaban-induced inhibition of Cmax by 20–56%, 12–26%
and 6–13% at 200, 500 and 1000 ng/mL rivaroxaban, respectively,
although not all values reached statistical signiﬁcance (Fig. 5B).
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Fig. 1. Reversal of rivaroxaban-induced prothrombin time (PT) prolongation by increasing concentrations of (A) recombinant activated factor VII (0, 5, 15, 50 μg/mL; n= 7), (B) activated
prothrombin complex concentrate (0, 0.2, 0.4, 0.7, 1.0 U/mL; n= 5), and (C) prothrombin complex concentrate (0, 0.2, 0.4, 0.7, 1.0 U/mL; n= 7) in human plasma. Rivaroxaban concen-
trations were 0, 200, 500 and 1000 ng/mL. Values are shown as mean x-fold change over baseline ± standard error of the mean. Baseline values were measured in the absence of
rivaroxaban and the reversal agent. *p b 0.05 vs. control, **p b 0.01 vs. control, ***p b 0.001 vs. control, †††p b 0.001 vs. rivaroxaban.
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concentration-dependently increased ETPby 37–62% (at concentrations
of 0.2–0.7 U/mL; Fig. 4C) and Cmax by 19–67% (at concentrations of
0.2–1.0 U/mL; Fig. 5C). All concentrations of PCC had a small – and in
most cases signiﬁcant – reversal effect of 5–15% on rivaroxaban-
induced prolongation of lag time (Fig. 3C). In plasma spiked with
200 ng/mL rivaroxaban, ETP was signiﬁcantly reversed by 70% with
0.2 U/mL PCC; at higher PCC concentrations of 0.4, 0.7 and 1.0 U/mL,
ETP increased above baseline and reached reversal levels of 105%,
118% and 143%, respectively (Fig. 4C). In plasma spiked with 500 and
1000 ng/mL rivaroxaban, ETP was reversed by 30–48% and 12–21%, re-
spectively, at all concentrations of PCC (Fig. 4C). PCC reversed the inhi-
bition of Cmax in plasma spiked with 200 ng/mL rivaroxaban by 8–14%
(not signiﬁcant) and had no reversal effect in plasma spiked with
500 ng/mL or 1000 ng/mL rivaroxaban (Fig. 5C).In summary, lag time of TG was partially reversed by all three
agents; rFVIIa had the greatest reversal effect followed by aPCC, and
PCC had the least effect. Whether ETP inhibition was completely
reversed or even overcompensated by aPCC or PCC was dependent on
the rivaroxaban concentration used to induce inhibition; aPCC was
more effective than PCC. rFVIIa showed a strong but only partial rever-
sal. rFVIIa and aPCC partially reversed rivaroxaban-induced inhibition
of Cmax; PCC had no effect (Table 1).
Discussion
Owing to the lack of predictive assays for the haemostatic efﬁcacy of
non-speciﬁc reversal agents, the studies presented in this article inves-
tigated the reversal potential of aPCC (FEIBA NF), PCC (Beriplex P/N)
and rFVIIa (NovoSeven) as measured by different clot-based assays
Table 1
Comparison of reversal effects of rFVIIa, aPCC and PCC on rivaroxaban-induced changes in PT and parameters (lag time, ETP, Cmax) of TG in plasma and CT (thrombelastometry) in whole
blood comparedwith the rivaroxaban effect in the absence of the reversal agent (% reversal± SEM). For comparison of the effectiveness, the lowest and thehighest concentration of rFVIIa,
aPCC and PCC tested were chosen and the clinical relevant concentrations for rivaroxaban.
Parameter Rivaroxaban
(ng/mL)
rFVIIa (µg/mL) aPCC (U/mL) PCC (U/mL) 
5 50 0.2 1.0 0.2 1.0 
PT prolongation  200 48 ± 1 47 ± 1 22 ± 3 38 ± 2 11 ± 4 16 ± 3 
500 55 ± 1 53 ± 1 32 ± 1 49 ± 3 19 ± 3 22 ± 1 
TG lag time prolongation 200 57 ± 1 57 ± 1 33 ± 3 47 ± 3 6 ± 6 13 ± 3 
500 53 ± 1 55 ± 1 35 ± 5 43 ± 5 5 ± 3 15 ± 3 
TG ETP inhibition  200 43 ± 4 39 ± 4 102 ± 2
b 181 ± 10b 70 ± 10 143 ± 8b
500 53 ± 2 56 ± 2 75 ± 11 132 ± 10b 30 ± 4 48 ± 9 
TG Cmax inhibition 200 14 ± 1 18 ± 1 20 ± 3 56 ± 8 8 ± 0.4 14 ± 1.1 
500 8 ± 1 12 ± 1 12 ± 3 26 ± 5 2 ± 0.2 3 ± 1.1 
CT prolongationa 200 37 ± 7 36 ± 10 23 ± 7 28 ± 10 –9 ± 4 –12 ± 4 
500 41 ± 3 37 ± 4 13 ± 7 24 ± 6 –9 ± 5 –7 ± 7 
Categorisation of strength of reversal was assessed by mean value of % reversal values per parameter.  
No reversal 
mean 0% 
Low reversal 
mean 15% 
Medium reversal 
mean 36% 
Strong reversal 
mean  51% 
Nearly complete 
or reversal >100%  
aConcentration of rivaroxaban and reversal agent are given as whole blood concentrations. In plasma, the appropriate concentrations were 331–358 ng/mL and 827–895 ng/mL
rivaroxaban, 9 and 87 μg/mL rFVIIa, 0.33 and 1.64 U/mL aPCC, 0.35 and 1.68 U/mL PCC.
bCalculated as increase of ETP over control value (%).
Abbreviations: aPCC, activated prothrombin complex concentrate; Cmax, maximum thrombin concentration; CT, clotting time; ETP, endogenous thrombin potential; PCC, prothrombin
complex concentrate; PT, prothrombin time; rFVIIa, recombinant activated factor VII; SEM, standard error of the mean; TG, thrombin generation.
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or PPP. Our goal was to assess the effects of potential reversal strategies
and to provide data on the strengths and limitations of these laboratory
assays.
It is important to note that different formulations of PCC are
available commercially. These differ regarding the inclusion of co-
agulation inhibitors (heparin, protein C, protein S, protein Z and an-
tithrombin) and in their content of coagulation factors (some
contain limited amounts of factor VII or differing amounts of factor
II, VII and X in relation to factor IX), which may lead to different re-
sults [33]. This study tested the reversal potential of the four-factor
PCC Beriplex P/N.
The results showed that rivaroxaban-induced prolongation of PT
(measured using Néoplastine®), CT and lag time of TG, and reduction
of Cmax and ETP of TG were in agreement with previously reported
data [32,34,35] and conﬁrmed that these assays are useful tools for
measuring the effects of factor Xa inhibition by rivaroxaban. Therefore,
these assays were used to estimate the reversal potential of non-
speciﬁc haemostatic agents.
All three haemostatic agents were partially effective in reversing
rivaroxaban-induced anticoagulation but showed different proﬁles.
Both factor VIIa-containing agents, rFVIIa and aPCC, weremore effective
than PCC in reversing the kinetic parameter of the initiation phase of
coagulation measured by PT, CT and lag time of TG. rFVIIa was more
effective than aPCC in the clot-based assays. However, even at the
highest concentration, rFVIIa and aPCC did not reduce clot times to
baseline; the reversal of PT, CT and lag time of TG reached a plateau at
approximately 50% or lower. In contrast, PCC only slightly reversed
rivaroxaban-induced prolongation of PT and lag time of TG and did
not affect CT. Both rFVIIa and aPCC alone shortened PT, CT and lag
time of TG, but PCC alone only slightly shortened PT, suggesting that
the reversal effect on clot timesmay at least be partly owing to the effect
of the agent itself on the measurement by accelerating the initiation
phase of coagulation. Furthermore, during the initiation phase, theamount of factor Xa generated is not sufﬁcient to overcome inhibition
by rivaroxaban and to neutralise the anticoagulant effect of rivaroxaban.
A previous study showed that when assessing concentrations of coagu-
lation factors generated during the initiation phase, only a small amount
of thrombin (26 ± 6.2 nM) and prothrombinase (1.3 pM) is generated
in a whole blood coagulation assay [36]. The plasma concentrations
of rivaroxaban used in our study were in the range 460–4100 nM
(MW 436 g). Therefore, clot-based assays may not precisely predict
the reversal potential of haemostatic agents because they measure the
initiation phase of coagulation and do not reﬂect the whole amount of
factor Xa generated during the coagulation process. Recently, similar
results were obtained by Körber et al. in an in vitro study demonstrating
that PCC caused no signiﬁcant reversal in PT and CT in human plasma
spiked with rivaroxaban [37]. rFVIIa signiﬁcantly reversed rivaroxaban-
induced prolongation of PT and CT [37]. Dinkelaar et al., also demonstrat-
ed that PCC did not result in normalisation of PT and TG lag time [38].
Furthermore, similar results were obtained with the factor Xa inhibitor
edoxaban, demonstrating the largest reversal effect on PT prolongation
by FVIIa, followed by aPCC and the smallest effect by PCC in vitro
in human plasma [39]. However, in contrast to our results Escolar et al.
recently showed that prolongation of CT by apixaban (ROTEM) was
completely reversed or even overcompensated by rFVIIa and aPCC; the
reversal effect with PCC was less pronounced [40]. These differences
may be explained by the use of a lower CaCl2 concentration for
recalciﬁcation (6 mM) in Escolar et al. [40].
The potential of PCC to reverse the anticoagulant effect of rivaroxaban
has also been investigated previously in healthy human subjects [26].
However, in this study, PCC 50 U/kg rapidly and completely reversed
the prolongation of PT induced by 20 mg twice-daily rivaroxaban [26].
The prolongation of PT with rivaroxaban was only 1.3-fold, indicating
that the PT reagent used (Siemens Healthcare Diagnostics, Marburg,
Germany) was less sensitive to rivaroxaban; therefore, the observed
complete reversal by PCC may have been as a result of the PT reagent
used rather than a ‘true’ reversal [26]. PT prolongation by rivaroxaban
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Fig. 2. Reversal of rivaroxaban-induced clotting time (CT) prolongation of the extrinsic coagulation pathway (r-extem reagent-induced and measured using thromboelastometry) by
(A) recombinant activated factor VII (0, 9 ± 0.9, 27 ± 0.9 and 87 ± 1.4 μg/mL; n = 4), (B) activated prothrombin complex concentrate (0, 0.33 ± 0.01, 1.16 ± 0.04, 1.64 ± 0.04 U/mL;
n = 5), and (C) prothrombin complex concentrate (0, 0.35 ± 0.01, 0.67 ± 0.01, 1.68 ± 0.05 U/mL; n = 2–3) in human whole blood. Individual plasma concentrations were calculated
for each individual donor by taking into account the individual haematocrit. All values are mean x-fold change over baseline ± standard error of the mean. Baseline values were measured
in the absence of rivaroxaban and the reversal agent. *p b 0.05 vs. control, **p b 0.01 vs. control, ***p b 0.001 vs. control, †p b 0.05 vs. rivaroxaban, ††p b 0.01 vs. rivaroxaban, †††p b 0.001 vs.
rivaroxaban.
676 E. Perzborn et al. / Thrombosis Research 133 (2014) 671–681varied depending on the reagent used [34], indicating that the extent
of reversal measured may depend on the thromboplastin reagent
used in the assay. In addition, it cannot be excluded that the differ-
ences in reversal, as reported by Eerenberg et al. and in our study,
stem from different study designs, namely in vivo versus in vitro, re-
spectively [26]. The in vivo administration of PCC could inﬂuence the
ﬁnal composition of PCC in plasma, and TF may have been exposed
at the site of blood withdrawal and may have inﬂuenced the ex vivo
measurements.When measuring TG, measurement of ETP refers to the total
amount of thrombin generated during the initiation, propagation
and ampliﬁcation phases of coagulation [35,41]. aPCC alone and
PCC alone, but not rFVIIa alone, concentration-dependently in-
creased the ETP over non­anticoagulated control values. Both aPCC
and PCC concentration-dependently reversed ETP reduction in-
duced by rivaroxaban. Complete neutralisation was obtained de-
pendent on both the rivaroxaban concentration and the aPCC or
PCC concentration. However, at clinically relevant concentrations
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677E. Perzborn et al. / Thrombosis Research 133 (2014) 671–681of rivaroxaban, PCC (at 200 ng/mL) and aPCC (at 200 ng/mL and
500 ng/mL) increased ETP over the control value at 0.7 U/mL (corre-
sponding to ~ 50 U/kg) and 1.0 U/mL. These data indicate that the
haemostatic agents tested have the potential to reverse the antico-
agulant effect of rivaroxaban and also show their prothrombotic po-
tential. rFVIIa partially corrected the ETP with a maximal effect of
39–56% at all concentrations of rivaroxaban. This may be caused
by enhancement of the TF pathway and the direct activation of
factor IX by rFVIIa [42]. However, at the concentrations described
in this study, rFVIIa did not reverse the thrombin generation
capacity or the clot-based parameters (PT, CT and lag time of TG)
in a concentration-dependent manner. This was in contrast to thereversal effects of aPCC and PCC. These results are in agreement
with those described by Desmurs-Clavel et al. [43], a similar study
that compared the reversal effects of rFVIIa, aPCC and PCC in
fondaparinux-anticoagulated platelet rich plasma. Importantly, we
observed a concentration-dependent reversal of rivaroxaban-
induced PT prolongation at concentrations of ≤ 5 μg/ml rFVIIa with a
minimum effective concentration of ~ 5 ng/mL, corresponding to
~ 0.27 μg/kg (data not shown).
Similar to our study, Dinkelaar et al. demonstrated that PCC
normalised total thrombin potential in rivaroxaban-spiked plasma
and whole blood in vitro [38]. Marlu et al. obtained similar results in
an ex vivo study that compared the effects of PCC (Konokad), aPCC
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had received 20 mg rivaroxaban [44]. In this study, PCC strongly re-
versed ETP, and aPCC reversed the kinetic parameters (lag time and
time to maximum thrombin concentration) and ETP [44]. rFVIIa
reversed the kinetic parameters, but in contrast to our study, rFVIIa
had no effect on ETP despite the use of higher rFVIIa concentrations.
Eerenberg et al. [26] measured the effect of PCC on the ETP in healthy
human subjects treated with rivaroxaban and also demonstrated com-
plete reversal of ETP. Complete reversal of ETP by aPCCwas also demon-
strated in human plasma spiked with the indirect factor Xa inhibitor
fondaparinux [43].
Rivaroxaban-induced inhibition of Cmax of TG was affected by the
three agents, with aPCC and PCC alone signiﬁcantly increasing Cmax
over baseline. However, the reversal effect was much less pronounced
compared with ETP. Rivaroxaban alone potently reduced Cmax, and to
a lesser extent ETP, with IC50 values of 20 ng/mL and 458 ng/mL
(mean of the three studies measuring the effects of PCC, aPCC and
rFVIIa), respectively. These results suggest that the main effect of
rivaroxaban-induced factor Xa inhibition is the delay of thrombinformation in the TG assay. Thus, in rivaroxaban-spiked plasma even in
the presence of aPCC, PCC or rFVIIa, the generation of thrombin and,
therefore, factor Xa is delayed, and the amount of factor Xa generated
is still insufﬁcient to neutralise rivaroxaban at the time point of Cmax.
Similarly, in the ex vivo study by Marlu et al. [44], the effect on Cmax
reversal was less pronounced compared with the effect on ETP.
In summary, the reversal of rivaroxaban-induced anticoagulation
by rFVIIa and aPCC may be assessed using PT, CT, lag time and ETP,
but not by Cmax. Owing to the concentration dependency of the reversal
effect needed to achieve maximal reversal demonstrated in this study,
ETP measurements may be more useful in predicting the reversal po-
tential of aPCC and PCC. In addition, measuring this parameter may
also indicate the prothrombotic potential of the haemostatic agent.
There are also various issues regarding the transferability of the
assays from the laboratory to daily clinical practice. Thromboelastometry
is a simple, point-of-care assay that is available in many hospitals. How-
ever, the sensitivity of the currently available CT assays is considered
insufﬁcient and a more sensitive CT assay would be highly desirable. In
contrast, TG assays are sensitive, but are not routinely available in the
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results are not immediately available. In addition, there are some general
limitations to be considered due to the nature of the assay. For example,
the reversal potential of PCC as measured by TG assays was dependent
on the concentration of TF in the assay [38]. Another study investigating
the reversal of apixaban-induced changes in TG by rFVIIa, aPCC or PCC,
also showed that the measured reversal effect was dependent on the
activating reagents [40]. Computational modelling data from healthy
subjects and patients showed that variations in TG did not mirror the
variations observed for factor Xa generation, and individuals with similar
TGproﬁles differed in their factor Xa generation proﬁles [45]. Importantly,
we used plasma from healthy volunteers in our study, which is a limita-
tion that needs to be considered when interpreting the results. In
addition, the TG assay may not fully reﬂect the biology of clot formation
in patients receiving anticoagulants.
A major limitation of all in vitro assays is that they do not mirror the
complex situation of the individual patient with a bleeding event, in-
cluding circulating bloodwith its cellular components and the damaged
vessel. It is, therefore, important to note, that there is no experience ofhow the reversal effects measured by laboratory assays correlate with
bleeding control or the reversal agents’ prothrombotic potential in the
clinical situation. We cannot exclude that the commercially available
laboratory assays may have poor predictive value for the management
of bleeding in patients treated with rivaroxaban. Therefore, clinical
studies are necessary to investigate which assay or assay conditions
best predict haemostasis in patients who are treated with rivaroxaban
and a reversal agent (e.g. in emergency situations).
The potential of aPCC, PCC and rFVIIa to reverse the anticoagulant
effect of rivaroxaban has also been investigated previously in animal
models, including rats, mice and baboons. In these studies, aPCC, PCC
and rFVIIa were shown to at least partially reverse the anticoagulant
effect of rivaroxaban, including PT and bleeding time ex vivo and in vivo
[27,28]. This was in contrast to a previous study in a rabbit hepatosplenic
haemorrhagicmodel,which demonstrated that rFVIIa and PCCdid not re-
duce rivaroxaban-induced bleeding [46]. However, it is noteworthy that
this study only tested the reversal potential of one concentration each of
PCC (40 U/mL) and rFVIIa (150 μg/kg), which may explain the lack of
reversal of rivaroxaban-induced bleeding reported [46].
680 E. Perzborn et al. / Thrombosis Research 133 (2014) 671–681The concentrations of rivaroxaban used for the current study have
been chosen to reﬂect maximum plasma concentrations expected after
taking 20 mg once-daily rivaroxaban (range 175–400 ng/mL) or an
extreme concentration to simulate overdose concentrations up to
1800 ng/mL. In healthy volunteers, there was a ceiling effect regarding
plasma concentrations caused by limited absorption at doses above
50mg [13]. In a previous study, themeanmaximal plasma concentration
of rivaroxaban was 316 ng/mL (range 185–532 ng/mL) after a single
dose of 80 mg rivaroxaban in healthy volunteers [47]. Thus, the extreme
concentrations tested in our study are unlikely to be achieved in clinical
practice. Similarly, the concentrations of the haemostatic agents studied
were chosen to reﬂect clinical practice, assuming a patient with a body
weight of 70 kg [24,30,31].
All three haemostatic agents alone – in the absence of rivaroxaban –
had a procoagulant effect on the parameters assessed. Moreover,
some results indicated that these agents had the potential to overcom-
pensate for the rivaroxaban-induced effect at lower concentrations of
rivaroxaban. Thus, it will be important to measure the anticoagulation
status of a patient before considering the use of a reversal agent in
patients experiencing a severe or life-threatening bleeding event
[13,48]. Moreover, to avoid increased risk of thromboembolic events,
the half-life of the reversal agent should be considered. Some coagula-
tion factors have a half-life of several hours and in patients in whom
the rivaroxaban plasma concentration is already declining, their appli-
cation may substantially increase thromboembolic risk. Clinical experi-
ence is required to evaluate the safety and efﬁcacy proﬁle of these
haemostatic agents in rivaroxaban-anticoagulated patients.
In summary, all three haemostatic agents – rFVIIa, aPCC and PCC –
were partially effective in reversing rivaroxaban-induced anticoagulation.
In the clotting assays, rFVIIa and aPCC had a higher reversal potential than
PCC, but reversal was not complete and reached a plateau. This limited
reversal effect may partly be caused by the effect of the agent itself on
the measurement (by accelerating the initiation phase of coagulation),
suggesting that clotting times may not correspond to the clinical effects,
and clotting assays may not precisely predict the reversal potential of
haemostatic agents (in particular PCC). ETP measurements may be
more predictive for assessing the reversal potential of PCC or aPCC, but
not of rFVIIa. Data from this study indicate that PT, CT and TG assays
cannot predict the exact dose of a reversal agent required to reverse
anticoagulation given a speciﬁc plasma concentration of rivaroxaban.
Therefore, more studies are required to establish the safety, efﬁcacy and
clinical utility of these agents for reversing the anticoagulant effect of
rivaroxaban in clinical practice.
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